Libido after menopause — the science worth knowing

The most-asked question in midlife women's health and the one most clinicians dodge. What actually changes biologically, what works (and what doesn't) — vaginal estrogen, systemic HRT, low-dose testosterone, DHEA — and the snake oil to skip.

The frequency curve of postmenopausal sexual desire is bimodal in the research: a subset of women experience minimal change, a larger subset experience meaningful decline in both desire and arousal, and a smaller subset actually report increased satisfaction (often tied to relational changes, removal of contraception/pregnancy concerns, more time, less stress). The biological mechanisms behind each pattern are now reasonably well-mapped.

What's frustrating is that the average primary-care visit treats this as either psychological, irrelevant, or beyond their expertise. The science is more concrete than the conversation usually suggests.

What changes biologically

Vaginal tissue itself

Estrogen decline directly affects vaginal tissue: thinning of the epithelium, reduced blood flow, decreased natural lubrication, increased pH (which changes the microbiome). This produces the cluster called genitourinary syndrome of menopause (GSM): dryness, dyspareunia (painful intercourse), urinary urgency, recurrent UTIs. GSM affects 50-80% of postmenopausal women. It's underdiagnosed because women don't bring it up and clinicians don't ask.

Brain-level desire

Estrogen and testosterone both modulate dopaminergic reward pathways. Testosterone in particular is more dominant in women's libido architecture than the lay understanding suggests — women produce testosterone in their ovaries and adrenals, and levels decline gradually through the 40s into menopause.

Stress, sleep, hormonal context

Sleep disruption (very common in menopause; see our sleep architecture letter) and cortisol patterns directly suppress libido independent of estrogen. Many women misattribute libido changes to menopause that are actually downstream of sleep + cortisol patterns.

What the evidence supports

Vaginal estrogen — first-line for GSM, dramatically under-prescribed

Local vaginal estrogen (creams, rings, tablets — Estrace, Premarin cream, Estring, Vagifem, Imvexxy) is the most evidence-backed, lowest-risk intervention for GSM. It works locally with minimal systemic absorption. The 2024 ACOG and NAMS position statements explicitly state that vaginal estrogen is safe for the vast majority of women including most breast cancer survivors (in coordination with oncology), and that the boxed warning on the packaging reflects systemic HRT data that doesn't apply to vaginal forms.

Why isn't it prescribed more? Two reasons: the misleading boxed warning frightens clinicians, and women don't bring up GSM symptoms in the limited primary-care visit time. If you have any GSM symptoms, this is the highest-leverage conversation to have. Most women see meaningful improvement within 4-6 weeks of starting.

Systemic HRT — improves desire for many but not all

Standard estradiol + progesterone HRT (covered in our HRT post-WHI letter) improves libido in some women but not most. The benefit is more indirect — better sleep, fewer hot flashes, better mood, all of which downstream-improve interest. If desire is your only complaint, HRT is not the first-line intervention.

Low-dose testosterone — the under-discussed option

The 2019 international consensus statement (Davis et al, Lancet Diabetes & Endocrinology) endorsed off-label low-dose testosterone for postmenopausal women with hypoactive sexual desire disorder (HSDD), provided menopausal hormone therapy is already optimized and other causes ruled out. Typical dosing is 1/10th the male replacement dose, delivered as a compounded cream applied to the inner thigh or as the off-label use of male products (Androgel) at female doses.

Effects show up over 8-12 weeks. Side effects at proper female doses are minimal (occasional acne, hirsutism in 5-10% of users at higher end of dose range). Liver effects, voice changes, and clitoromegaly are essentially nonexistent at properly dosed levels.

The U.S. has no FDA-approved female testosterone product (a long political story), so prescribing is off-label or via compounding pharmacies. Australia has one (AndroFeme). Most prescribers in the US who do this routinely are women's-health specialists rather than primary care.

DHEA — limited but specific use case

Intravaginal DHEA (prasterone, Intrarosa) is FDA-approved for moderate-to-severe dyspareunia in postmenopausal women. It works by being converted to estrogen and testosterone locally in the vaginal tissue, with minimal systemic exposure. A good option for women who want a non-estrogen alternative for GSM. Oral DHEA supplements are different and have weak evidence.

Flibanserin (Addyi) and bremelanotide (Vyleesi)

Both FDA-approved for premenopausal HSDD only, not postmenopausal. Effect sizes are modest, side effects (hypotension with flibanserin, especially with alcohol) are nontrivial. Most women's-health specialists don't recommend either as first-line for postmenopausal libido issues.

What to skip

• Herbal libido supplements (maca, horny goat weed, tongkat ali, fenugreek) — evidence base ranges from thin to placebo-level for postmenopausal women specifically. Some have mild effects in younger populations or men; the postmenopausal-women trials are mostly weak or unfunded.
• "Bioidentical" pellet therapies marketed by wellness clinics — pellets deliver supraphysiological hormone doses with non-adjustable dosing. The 2017 NAMS position statement specifically warned against them due to inability to titrate, batch-to-batch quality issues, and supraphysiological dosing risks.
• CBD / cannabinoid topicals marketed for sexual function — interesting category but evidence is anecdotal; not first-line.

After Forty Feel is independent editorial. Reader-funded. No supplement-brand or pharmaceutical-brand sponsorships, ever. This letter is informational and not a substitute for medical advice.